Meta Analysis Of A Randomized Controlled Trial Of Xiaoqinglong Decoction In The Treatment Of Bronchial Asthma

Objective:To systematically evaluate the clinical efficacy of xiaoqinglong decoction combined with western medicine in the treatment of bronchial asthma.Methods:1.The system to retrieve the Pub Med database in English and China National Knowledge Infrastructure(CNKI),ten thousand party data knowledge service platform,Wipo Chinese journal full text database(VIP)and Chinese biomedical literature database(CBM),collected before January 1,2019 xiaoqinglong decoction reduction combined with western medicine in the treatment of bronchial asthma(RCTs)randomized controlled study.2.The conventional western medicine group was mainly treated with conventional western medicine,such as: budesonide atomization,shulidian or xinbikeke inhalation,anti-infection,spasmolysis and antiasthmatic conventional treatment;Xiaoqinglong decoction group was treated by oral administration of xiaoqinglong decoction or xiaoqinglong decoction granules on the basis of conventional treatment group of western medicine.3.The curative effect of standard statistical analysis of two main groups of lung function FEV1(forced expiratory volume in 1second),FEV1 / FVC ratio(forced expiratory volume in 1 second and forced vital capacity percentage level)to improve the situation of biochemical indicators eosinophil count absolutely(EOS),immunoglobulin E(Ig E)and the clinical curative effect of breathing and symptoms of wheezing sound integral to asthma.4.Statistical analysis method: the Rev Man 5.3 software provided by Cochrane collaboration was used for data processing and quality assessment,and subgroup analysis was performed when necessary.P<0.05 was considered statistically significant,while P>0.05 was not.Results:1.A total of 37 RCTs were included in this study,including a total of 2922 patients with bronchial asthma.The RCTs methodological study was of low quality,and one was a placebo controlled study.2.Meta analysis results showed that,compared with the conventional western medicine group,the treatment of xiaoqinglong decoction combined with western medicine significantly improved the FEV1[MD=0.24,95%CI(0.21,0.28),Z=15.42,P < 0.0,001],increased the ratio of FEV1/FVC [MD=3.17,95%CI(2.64,3.69),Z=11.88,P < 0.00001],and significantly reduced the EOS value[MD=-0.01,95%CI(-0.01,-0.01),Z=4.25.P <0.0001],decreased Ig E level [MD=-12.13,95%CI(-13.14,-11.12),Z=23.47,P<0.00001],improved wheezing symptoms [MD=-0.92,95%CI(-1.00,-0.84),Z=22.95,P < 0.00001],decreased asthma symptom score [MD=-0.44,95%CI(-0.57,-0.32),Z=6.97,P< 0.00001].No adverse reactions were reported in RCTs included in the study.